Molecular and biochemical features in Alzheimer's disease
- PMID: 17105434
- DOI: 10.2174/138161206778792967
Molecular and biochemical features in Alzheimer's disease
Abstract
The purpose of this review is to discuss the pathophysiological pathways involved in pathogenesis of Alzheimer's disease pointing out current and future pharmacological targets. Alzheimer's disease is one of the most important neurodegenerative disorders in the developed world together with Parkinson's disease. Although this disease was described almost a century ago, the molecular mechanisms that lead to the development of the neuronal pathology are not clear at the moment. Furthermore, although enormous efforts have been done, an efficient treatment for the disease does not exist yet because the mechanism of neuronal cell death is unknown. In the present work we discuss, in depth, the potential mechanisms involved in apoptosis and neuronal death in Alzheimer's disease. The biology, structure and physiological properties of beta-amyloid peptide and related proteases (secretases) are discussed, as well as existing therapeutics and future strategies for the treatment of Alzheimer's disease. Inhibition of production of amyloid peptides by secretase inhibitors has been suggested as one of the most rational and specific therapeutic approaches. Inhibition of apoptosis mediated by oxidative stress generation and mitochondrial alteration, or blockade of NMDA receptors could constitute suitable therapeutic strategies for Alzheimer's disease. Finally, a multiple therapy with antioxidants, cell cycle inhibitors and other drugs modulating APP processing could be, in the future, a suitable strategy in order to delay Alzheimer's disease progression.
Similar articles
-
Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases.Curr Pharm Des. 2011;17(3):230-45. doi: 10.2174/138161211795049732. Curr Pharm Des. 2011. PMID: 21348832 Review.
-
Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches.Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):43-65. doi: 10.1358/mf.2008.30.1.1090962. Methods Find Exp Clin Pharmacol. 2008. PMID: 18389097 Review.
-
Alzheimer's disease.Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review.
-
Alzheimer's disease pathogenesis and therapeutic interventions.J Clin Neurosci. 2004 Jun;11(5):456-67. doi: 10.1016/j.jocn.2003.12.007. J Clin Neurosci. 2004. PMID: 15177383 Review.
-
Therapeutic potential of oxidant mechanisms in Alzheimer's disease.Expert Rev Neurother. 2004 Nov;4(6):995-1004. doi: 10.1586/14737175.4.6.995. Expert Rev Neurother. 2004. PMID: 15853526 Review.
Cited by
-
NMDA Receptor Function During Senescence: Implication on Cognitive Performance.Front Neurosci. 2015 Dec 16;9:473. doi: 10.3389/fnins.2015.00473. eCollection 2015. Front Neurosci. 2015. PMID: 26732087 Free PMC article. Review.
-
Polyphenols as therapeutic molecules in Alzheimer's disease through modulating amyloid pathways.Mol Neurobiol. 2015 Apr;51(2):466-79. doi: 10.1007/s12035-014-8722-9. Epub 2014 May 15. Mol Neurobiol. 2015. PMID: 24826916 Review.
-
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Curr Neuropharmacol. 2012 Sep;10(3):272-85. doi: 10.2174/157015912803217288. Curr Neuropharmacol. 2012. PMID: 23450042 Free PMC article.
-
Computational Evaluation of Interaction Between Curcumin Derivatives and Amyloid-β Monomers and Fibrils: Relevance to Alzheimer's Disease.J Alzheimers Dis. 2021;82(s1):S321-S333. doi: 10.3233/JAD-200941. J Alzheimers Dis. 2021. PMID: 33337368 Free PMC article.
-
Green Tea, A Medicinal Food with Promising Neurological Benefits.Curr Neuropharmacol. 2021;19(3):349-359. doi: 10.2174/1570159X18666200529152625. Curr Neuropharmacol. 2021. PMID: 32469701 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical